Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1982 5
1983 5
1984 9
1985 18
1986 18
1987 34
1988 56
1989 87
1990 114
1991 131
1992 165
1993 264
1994 331
1995 424
1996 479
1997 526
1998 593
1999 641
2000 815
2001 1008
2002 1162
2003 1590
2004 2035
2005 2754
2006 3181
2007 3774
2008 4776
2009 5647
2010 6785
2011 8408
2012 10042
2013 12096
2014 13700
2015 14821
2016 9839
2017 7164
2018 10835
2019 12398
2020 14391
2021 16069
2022 17976
2023 15704
2024 4268

Text availability

Article attribute

Article type

Publication date

Search Results

181,842 results

Results by year

Filters applied: . Clear all
Page 1
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
Zhao Q, Jiang Y, Xiang S, Kaboli PJ, Shen J, Zhao Y, Wu X, Du F, Li M, Cho CH, Li J, Wen Q, Liu T, Yi T, Xiao Z. Zhao Q, et al. Among authors: zhao y. Front Immunol. 2021 Mar 30;12:658753. doi: 10.3389/fimmu.2021.658753. eCollection 2021. Front Immunol. 2021. PMID: 33859650 Free PMC article. Review.
In order to re-activate T cells against tumors, immune-mobilizing monoclonal TCRs against cancer (ImmTAC) have been developed as a novel class of manufactured molecules which are bispecific and recognize both cancer and T cells. ...New approaches that can better det …
In order to re-activate T cells against tumors, immune-mobilizing monoclonal TCRs against cancer (ImmTAC) have been developed as a no …
The application of CAR-T cell therapy in hematological malignancies: advantages and challenges.
Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. Zhao Z, et al. Acta Pharm Sin B. 2018 Jul;8(4):539-551. doi: 10.1016/j.apsb.2018.03.001. Epub 2018 Apr 5. Acta Pharm Sin B. 2018. PMID: 30109179 Free PMC article. Review.
Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). The CAR-T cell is an effector T cell that recognizes a …
Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are enginee …
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA. Kochenderfer JN, et al. Among authors: zhao y. J Immunother. 2009 Sep;32(7):689-702. doi: 10.1097/CJI.0b013e3181ac6138. J Immunother. 2009. PMID: 19561539 Free PMC article.
The transduced T cells specifically killed primary chronic lymphocytic leukemia (CLL) cells. We transduced T cells from CLL patients that had been previously treated with chemotherapy. ...
The transduced T cells specifically killed primary chronic lymphocytic leukemia (CLL) cells. We transduced T cells from CLL pa …
Resident memory T cells form during persistent antigen exposure leading to allograft rejection.
Abou-Daya KI, Tieu R, Zhao D, Rammal R, Sacirbegovic F, Williams AL, Shlomchik WD, Oberbarnscheidt MH, Lakkis FG. Abou-Daya KI, et al. Among authors: zhao d. Sci Immunol. 2021 Mar 19;6(57):eabc8122. doi: 10.1126/sciimmunol.abc8122. Sci Immunol. 2021. PMID: 33741656 Free PMC article.
Tissue-resident memory T cells (T(RM)) contained at sites of previous infection provide local protection against reinfection. ...Thus, recipient effector T cells differentiate into functional graft T(RM) that maintain rejection locally. ...
Tissue-resident memory T cells (T(RM)) contained at sites of previous infection provide local protection against reinfection. …
In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy.
Xin T, Cheng L, Zhou C, Zhao Y, Hu Z, Wu X. Xin T, et al. Among authors: zhao y. Front Oncol. 2022 Feb 10;12:809754. doi: 10.3389/fonc.2022.809754. eCollection 2022. Front Oncol. 2022. PMID: 35223491 Free PMC article. Review.
Chimeric antigen receptor T cell (CAR-T cell) therapy has shown impressive success in the treatment of hematological malignancies, but the systemic toxicity and complex manufacturing process of current autologous CAR-T cell therapy hinder its broader applicat …
Chimeric antigen receptor T cell (CAR-T cell) therapy has shown impressive success in the treatment of hematological malignanc …
Delivery of CD47 blocker SIRPalpha-Fc by CAR-T cells enhances antitumor efficacy.
Chen H, Yang Y, Deng Y, Wei F, Zhao Q, Liu Y, Liu Z, Yu B, Huang Z. Chen H, et al. Among authors: zhao q. J Immunother Cancer. 2022 Feb;10(2):e003737. doi: 10.1136/jitc-2021-003737. J Immunother Cancer. 2022. PMID: 35110357 Free PMC article.
Given the antitumor activity against preclinical model of CD47-blocking to induce the innate and adaptive immune system in the tumor microenvironment, here we developed a CAR-T cell secreting CD47 blocker signal regulatory protein alpha (SIRPalpha)-Fc fusion protein (Sirf …
Given the antitumor activity against preclinical model of CD47-blocking to induce the innate and adaptive immune system in the tumor microen …
SENP7 senses oxidative stress to sustain metabolic fitness and antitumor functions of CD8+ T cells.
Wu Z, Huang H, Han Q, Hu Z, Teng XL, Ding R, Ye Y, Yu X, Zhao R, Wang Z, Zou Q. Wu Z, et al. Among authors: zhao r. J Clin Invest. 2022 Apr 1;132(7):e155224. doi: 10.1172/JCI155224. J Clin Invest. 2022. PMID: 35143421 Free PMC article.
The functional integrity of CD8+ T cells is tightly coupled to metabolic reprogramming, but how oxidative stress directs CD8+ T cell metabolic fitness in the tumor microenvironment (TME) remains elusive. ...Importantly, lowering T cell-intrinsic ROS restricte …
The functional integrity of CD8+ T cells is tightly coupled to metabolic reprogramming, but how oxidative stress directs CD8+ T …
30-color full spectrum flow cytometry panel for deep immunophenotyping of T cell subsets in murine tumor tissue.
Liu Y, Xu X, Liu D, Wu X, Gao Y, Wang H, Yan F, Yang W, Zhao D, He F, Tang L. Liu Y, et al. Among authors: zhao d. J Immunol Methods. 2023 May;516:113459. doi: 10.1016/j.jim.2023.113459. Epub 2023 Mar 16. J Immunol Methods. 2023. PMID: 36931458
The panel presented here first identify the main cell subsets including myeloid cells, B cells, NKT cells, gammadelta T cells, CD4(+) T cells and CD8(+) T cells. For CD4(+) T cells or CD8(+) T cells, the panel includes markers for further charac …
The panel presented here first identify the main cell subsets including myeloid cells, B cells, NKT cells, gammadelta T cells, CD4(+) …
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.
Hu B, Ren J, Luo Y, Keith B, Young RM, Scholler J, Zhao Y, June CH. Hu B, et al. Among authors: zhao y. Cell Rep. 2017 Sep 26;20(13):3025-3033. doi: 10.1016/j.celrep.2017.09.002. Cell Rep. 2017. PMID: 28954221 Free PMC article.
The effects of transgenically encoded human and mouse IL-18 on T cell proliferation and its application in boosting chimeric antigen receptor (CAR) T cells are presented. ...In an intact mouse tumor model, CD19-IL-18 CAR T cells induced deeper B cell aplasia, …
The effects of transgenically encoded human and mouse IL-18 on T cell proliferation and its application in boosting chimeric antigen …
Single-cell analyses of Crohn's disease tissues reveal intestinal intraepithelial T cells heterogeneity and altered subset distributions.
Jaeger N, Gamini R, Cella M, Schettini JL, Bugatti M, Zhao S, Rosadini CV, Esaulova E, Di Luccia B, Kinnett B, Vermi W, Artyomov MN, Wynn TA, Xavier RJ, Jelinsky SA, Colonna M. Jaeger N, et al. Among authors: zhao s. Nat Commun. 2021 Mar 26;12(1):1921. doi: 10.1038/s41467-021-22164-6. Nat Commun. 2021. PMID: 33771991 Free PMC article.
Further analyses comparing tissues from non-inflamed and inflamed regions of patients with CD versus healthy controls show increased activated T(H)17 but decreased CD8(+)T, gammadeltaT, T(FH) and Treg cells in inflamed tissues. Similar analyses of LP find inc …
Further analyses comparing tissues from non-inflamed and inflamed regions of patients with CD versus healthy controls show increased activat …
181,842 results
You have reached the last available page of results. Please see the User Guide for more information.